Canada Markets closed

Awakn Life Sciences Corp. (AWKN.NE)

NEO - NEO Real Time Price. Currency in CAD
Add to watchlist
0.3300+0.0100 (+3.13%)
At close: 01:32PM EST
Full screen
Previous Close0.3200
Open0.3200
Bid0.3200 x N/A
Ask0.3400 x N/A
Day's Range0.3200 - 0.3300
52 Week Range0.2500 - 2.0500
Volume7,136
Avg. Volume21,834
Market Cap8.148M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.6460
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.75
  • Newsfile

    Awakn Life Sciences Initiates Investigative Study of Novel Formulation of (S)-ketamine to Assess Dissociative Effect

    Study Has Potential to Lead to In-Licensing Agreement and Accelerated Pathway to Phase II Toronto, Ontario--(Newsfile Corp. - January 24, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces today it has initiated an investigative study to establish the dissociative effect of a proprietary and patent pending formulation of (S)-ketamine a

  • Market Exclusive

    Weekly Roundup on the Cannabis Sector & Psychedelic Sector

    Key Takeaways; Cannabis Sector 22nd Century announced partnerships with Core-Mark and Eby-Brown, two of the largest U.S. convenience store distributors. Scotts Miracle-Gro announced timing for Q1 financial results and conference call. Tilray’s revenue declines as net losses increase; if cannabis sales continue to be slow, the company may switch to fruit and beer sales. Key […] The post Weekly Roundup on the Cannabis Sector & Psychedelic Sector appeared first on Market Exclusive.

  • Newsfile

    Awakn Life Sciences Reports Strong Q3 2022 Results with 27% Revenue Growth

    And continued successful execution of R&D and Commercialization strategies Toronto, Ontario--(Newsfile Corp. - December 15, 2022) - Awakn Life Sciences Corp.(NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a biotechnology company, researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announced today its financial results and business highlights for the three months ended October 31, 2022. All results are reported under